
    
      OBJECTIVES: I. Expand access to Campath-1H for patients with refractory prolymphocytic
      leukemia or chronic lymphocytic leukemia.

      OUTLINE: Patients receive Campath-1H IV over 2 hours on days 1, 3, and 5. Treatment repeats
      weekly for 4-12 weeks in the absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: Not specified
    
  